We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.62 | -1.64% | 97.44 | 98.22 | 97.44 | 97.76 | 1,562,845 | 01:00:00 |
From Apr 2019 to Apr 2024
By Michael Dabaie
Knight Therapeutics Inc. said it would acquire the exclusive rights to manufacture, market and sell Exelon in Canada and Latin America from Novartis AG.
Montreal-based Knight said it is also acquiring an exclusive license to use the intellectual property and the Exelon trademark within the territory.
Exelon is a prescription product first approved in 1997 and is currently registered and sold in about 90 countries. Exelon is indicated for mild to moderately severe dementia in people with Alzheimer's disease.
Knight will pay $168 million in cash and an additional milestone payment of up to $12 million.
Exelon had annual revenue for 2020 of about $47 million for Canada and Latin America, Knight said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 23, 2021 08:26 ET (12:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
